Background Patients with Crigler-Najjar syndrome, type I (CNS-I) have an inherited absence of hepatocellular bilirubin uridine diphosphate-glucuronosyltransferase activity, which results in severe unconjugated hyperbilirubinaemia, often causing kernicterus and death in infancy or childhood.
Introduction
Crigler-Najjar syndrome, type I (CNS-I) is a rare disease. The inheritance is autosomal recessive, and the usual ¢ndings are icterus, non-haemolytic jaundice and a complete lack of hepatocellular bilirubin uridine diphosphate-glucuronosyltransferase (UGT, EC 2.4.1.17) activity. 1, 2 The gene has ¢ve exons coding for the enzyme (UGT-1) and is located on chromosome 2q37. The enzyme de¢ciency is caused by a deletion or nucleotide substitution in exons 1-3 and/or 4. 3^7 Nearly all patients with CNS-I eventually show damage to the central nervous system. Death is common in the ¢rst year of life for untreated individuals, and kernicterus with yellow deposits in the brain are the usual ¢ndings at autopsy. The lipophilic, non-protein bound unconjugated bilirubin (UB) partitions into the lipophilic cell membranes of the central nervous system and leads to hyperbilirubinaemic encephalopathy. 8^10 We reported earlier that maintaining the concentration of protein-bound bilirubin (PBB) lower than the binding capacity of albumin is important in preventing neurological damage. 11 Phenobarbital is ine¡ective in decreasing the PBB in patients with CNS-I, because there is no conjugating enzyme (UGT) present that can be stimulated. Although liver transplantation has been proposed as the curative therapy, 12 the optimal time for the transplantation is not known. In the absence of marked increases in PBB and kernicterus, most patients with CNS-I are treated with conservative therapy. The concentration of PBB in plasma can be transiently reduced by phototherapy, exchange transfusion, 13^15 or by plasma perfusion. 16, 17 Phototherapy is e¡ective in babies, but not in adults because of the more opaque skin in the latter. Exchange transfusion is e¡ective in adults in reducing the UB and PBB, but the procedure is lengthy and each treatment requires signi¢cant amounts of fresh whole blood or albumin.
Our goal in this study was to judge the e¤cacy of removing UB and PBB from blood by phototherapy and/or plasma perfusion. The observations described here were mainly derived from bilirubin assays performed over a 19-year period on our patient with CNS-I.
Patient and methods

Patient
We described certain aspects of this case in an earlier report. 11 The patient is a 19-year-old Japanese man with CNS-I who exhibited unconjugated hyperbilirubinaemia soon after birth. He was diagnosed as having CNS-I on the basis of a complete absence of hepatic UGT activity in a liver biopsy sample obtained at the age of 51days. He received phototherapy shortly after birth. At the age of 15 years, nucleotide sequencing of the UGT gene revealed a point mutation of TGC (cysteine) to TGA, a chain terminator codon, at position 840 in exon 1A. 7 Phototherapy e¡ectively reduced his serum bilirubin and prevented the likely sequelae of CNS-I. Since birth, he had been treated with phototherapy for more than 10 h every night under 30 £uorescent lamps (40 W). His conjugated bilirubin (CB) was undetectable. At the age of16 years, he was diagnosed as neurologically normal with no apparent defects. His auditory brain-stem response was within normal limits; his serum bilirubin: albumin molar ratio was 50.8 and UBwas 510 nmol/ L (UB reference value 520 nmol/ L). 18 However, his serum bilirubin concentrations continued to increase over subsequent years. At the age of 16 years and 1 month, an abrupt deterioration of the patient's ability to walk and speak occurred when the PBB and UB concentrations were elevated to 802 mmol/ L and 18.8 nmol/ L, respectively, with the bilirubin:albumin molar ratio being 1.14. At this time, phototherapy had little e¡ect in decreasing the PBB. We then performed plasma perfusion by ¢ltering his plasma through a column containing an anion-exchange resin. We obtained data for 7 months, from the age of 16 years and 2 months (the beginning of perfusion) up to the age of 16 years and 8 months. At that time, the patient received a liver transplant from a dead donor. Written informed consent was obtained from the patient, and the treatment was approved by the Protection of Human Rights Committee of Toho University.
Methods
In the perfusion studies, plasma was passed through a bilirubin-adsorbent column (Plasorba BR-350, Asahi Medical Co Ltd,Tokyo, Japan) to remove bilirubin from plasma (see Fig. 1 ). We used a fresh column for each plasma perfusion. Blood was drawn from the radial artery at a £ow rate of 160 mL/min and pumped into a membrane plasma separator (Plasmacure PS-06, Kuraray, Okayama, Japan). The plasma yield was 40 mL/min.We passed the plasma through the column containing the anion-exchange resin and returned the treated plasma to the patient. The bilirubinadsorbent resin consisted of a strong-base resin (quaternary amine) in the chloride form. We used a cellulose acetate ¢lter at the e¥uent from the column with a 0.45-mm pore size. During the perfusion, sodium heparin was added to the blood in the separator at a rate of 1000 U/h. The total volume of perfused plasma was 7 L after 3 h of perfusion. We collected a 3-mL aliquot of plasma after 2, 4 and 7 L of perfusion at the inlet and outlet of the pheresis system (see Fig. 1 , sites Pads and Pv). This procedure was followed at 3-day intervals for about 1 year. We determined the concentration of PBB (as total bilirubin) and UB with the UB analyser (Arrows Co, Osaka, Japan). 19 Here, the UB analyser measured the UB concentration as described by Nakamura and Lee using a bilirubin oxidation reaction with horseradish peroxidase. 20 Bilirubin was oxidized to colourless compounds by peroxidase in the presence of hydrogen peroxide derived from glucose by glucose oxidase. The analyser calculated the concentration of UB from the decrease of absorbance at 460 nm, although (EZ)cyclobilirubin present in the patient's serum potentially interfered with the oxidation reaction. 21 With each run, we assayed a quality control specimen containing 11.1 nmol/ L of UB.
In our patient, the daily production of bilirubin from the haemoglobin of erythrocytes was calculated as follows: 22, 23 Bilirubin production in mmol/day=(haemoglobin in whole blood in g/L)6(body weight in kg)/ 1360.03861/12061/585610 6 where (body weight in kg)/13 is the blood volume in litres, 0.038 is four times the molecular weight ratio of haem (616.5) to haemoglobin (64 500), 120 is the mean lifespan of erythrocytes in days and 585 is the molecular weight of bilirubin. In the calculation of the bilirubin:albumin molar ratio, 68 000 was used for the molecular weight of albumin. The data were analysed by Wilcoxon signed-rank test, and di¡erences of P50.05 were considered to be statistically signi¢cant.
Results
Ef ciency of phototherapy
Plasma concentrations of PBB and UB in the pretransplantation period are shown in Fig. 2 from the age of 4 years to16 years and 8 months. At the age of 5 years, we estimated the e¤ciency of phototherapy for the elimination of bilirubin (see Table 1 ). Before the start of nightly phototherapy, his PBB was 305 mmol/L and UB was 4.1 nmol/ L. The PBB and UB determined next morning had decreased to 242 mmol/L and 2.7 nmol/ L, respectively. The decreases were 21% and 34% of the expected PBB and UB concentrations, respectively. Because phototherapy facilitates the excretion of bilirubin into bile in the form of bilirubin photoisomers, 92 mmol of PBB was removed by 10 h of phototherapy. Although this amount of PBB almost matched the daily production, the plasma PBB concentration gradually increased and reached 776 mmol/L at the age of 15 years and 11 months (with a bilirubin:albumin molar ratio of 1.08). At that time, the UB concentration was 21.7 nmol/ L; however, neurobehavioural dysfunction was not observed in our patient, which indicated the presence of a functionally mature blood-brain barrier that a¡ords older patients resistance to the neurotoxic action of UB. 24, 25 When our patient was 16 years and 1 month old, an abrupt deterioration of his neurological status occurred as previously described. We also observed slower EEG waves and a decrease in amplitude of the auditory brain-stem response. Because the patient's bilirubin:albumin molar ratio of 1.14, and PBB and UB concentrations had increased to 802 mmol/L and 18.8 nmol/ L, respectively, we concluded that phototherapy was no longer su¤cient, and hence started plasma perfusion to reduce the bilirubin. After 24 h of phototherapy and plasma perfusion through the anion-exchange resin, his PBB and UB concentrations were markedly reduced and his neurological state returned to normal. Table 2 shows the concentrations of PBB, UB and albumin from three perfusions performed on three successive days when the patient was 16 years and 7 months old. Plasma specimens were collected at the inlet and outlet of the bilirubin adsorbent column (see Fig. 1 , sites Pads and Pv) after 2, 4 and 7 L of perfusion. The concentrations of PBB, UB and albumin were decreased signi¢cantly (P50.05) after plasma perfusion. UB was removed by plasma perfusion with an e¤ciency similar to that of PBB (P50.05). The e¤ciency of perfusion was reduced when the perfusion volume reached 7 L. Adsorption of albumin to the column was as low as 0-13% (0-5 g/L). However, both UB and PBB returned to the pre-perfusion concentrations on the following day (see Fig. 2 ). At the age of 16 years, plasma perfusion could barely remove the bilirubin synthesized each day (see Table 1 ). patient's original liver size. At 9 months after liver transplantation, the concentrations of PBB and UB were dramatically decreased to 22-29 mmol/L (reference value 517 mmol/ L) and to 0.2 nmol/ L, respectively (see Fig. 2 ). However, at that time, we found 3-14 mmol/ L of CB (reference value 53 mmol/L) accompanied by other enzyme changes, as shown in Table 3 . These abnormalities may indicate subacute and mild rejection of the liver graft.
Ef ciency of plasma perfusion
Effect of liver transplantation
Discussion
Liver transplantation is the most e¡ective treatment for CNS-I and is potentially curative provided a compatible donor is available. The stress of surgery, transplant rejection and other complications can be overcome. Besides CNS-I, our patient was a young man in good health, which was a major advantage for receiving transplantation. Although treatments by phototherapy and plasma perfusion eventually led to an increase in PBB and UB, these treatments are useful means to reduce PBB and UB in the short term. In our patient, 21% of PBB and 34% of UB were removed by 10 h of phototherapy, and 45% and 43%, respectively, were removed by 3 h of plasma perfusion. In babies, the reduction of PBB by phototherapy has been reported as 14 -33% or 8-27%. 26, 27 These reports support the view that phototherapy was an appropriate treatment for our patient until he was 15 years old.
Geiger et al. 17 reported that PBB and CB were adsorbed equally by the same type of column that we used. They studied conjugated hyperbilirubinaemia and little of unconjugated hyperbilirubinaem ia. The percentage adsorption of PBB and CB to the column is reportedly about the same, while the binding a¤nity of unconjugated bilirubin to albumin is stronger than that of CB to albumin. 28 During perfusion, CB was easily freed from albumin. Therefore, we deduced that PBB and CB were unbound from albumin and adsorbed to the column. In fact, albumin adsorbed to the column was only 0-13% of the pre-perfusion values.
Unconjugated bilirubin was apparently adsorbed to the column with the same e¤ciency as PBB. Moreover, UB at 43.3 nmol/ L was not completely removed by 4 L of perfusion, although the column still had a potential of removing 47 mmol/L of PBB in the next 7 L of perfusion (see Table 2 ). This leads to the question of whether UB was truly adsorbed to the column. Our ¢ndings rather support the notion that UB would be reproduced from PBB, according to the molar ratio of bilirubin to albumin immediately after termination of the treatment. 29 This means that it is not necessary to calculate the e¤ciency of removal of UB by the column. The same might be true for the phototherapy.
We conclude that daily production of bilirubin in our patient at the age of 5 years could be removed by timely phototherapy, and at the age of 16 years by plasma perfusion through an anion-exchange resin column. Elevated UB values also responded to intensive treatment with both phototherapy and plasma perfusion, but these procedures could give only temporary relief. In retrospect, our patient should have been treated with liver transplantation at the age of 12-15 years, when phototherapy no longer became e¡ective. 30 Clearly, liver transplantation is curative by providing the active enzyme necessary for the conjugation of bilirubin. We now know much about genotyping for accurate diagnosis of CNS-I, techniques of transplantation and the use of immunosuppressants so that the 5-year survival rate of liver recipients is markedly improved. 
